Format

Send to

Choose Destination
Ann Oncol. 2015 Jul;26(7):1291-9. doi: 10.1093/annonc/mdv022. Epub 2015 Jan 20.

Genetics of breast cancer: a topic in evolution.

Author information

1
Divison of Medical Oncology, University of Washington, Seattle Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA shiovitz@uw.edu.
2
Divison of Medical Oncology, University of Washington, Seattle Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA.

Abstract

A hereditary predisposition to breast cancer significantly influences screening and follow-up recommendations for high-risk women. However, in patients with a suggestive personal and/or family history, a specific predisposing gene is identified in <30% of cases. Up to 25% of hereditary cases are due to a mutation in one of the few identified rare, but highly penetrant genes (BRCA1, BRCA2, PTEN, TP53, CDH1, and STK11), which confer up to an 80% lifetime risk of breast cancer. An additional 2%-3% of cases are due to a mutation in a rare, moderate-penetrance gene (e.g. CHEK2, BRIP1, ATM, and PALB2), each associated with a twofold increase in risk. Prediction models suggest that there are unlikely to be additional yet to be identified high-penetrance genes. Investigation of common, low-penetrance alleles contributing to risk in a polygenic fashion has yielded a small number of suggestive single-nucleotide polymorphisms (SNPs), but the contributive risk of an individual SNP is quite small. Mutation testing is currently recommended for individual genes in the appropriate clinical setting where there is a high index of suspicion for a specific mutated gene or syndrome. Next-generation sequencing offers a new venue for risk assessment. At the present time, there are clear clinical guidelines for individuals with a mutation in a high-penetrance gene. Otherwise, standard models are used to predict an individual's lifetime risk by clinical and family history rather than genomic information.

KEYWORDS:

BRCA; breast cancer; family history; genetics; multiplex gene panels; screening

PMID:
25605744
PMCID:
PMC4478970
DOI:
10.1093/annonc/mdv022
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center